Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals

London, Ontario, July 9, 2025 — Sernova Biotherapeutics Inc. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) has announced a significant collaboration with Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) aimed at advancing a potential functional cure for Type 1 Diabetes (T1D). This partnership focuses on evaluating Eledon’s investigational immunosuppressive agent, tegoprubart (AT-1501), within Sernova’s ongoing Phase 1/2 clinical trial of its innovative Cell Pouch Bio-hybrid Organ.

Key Details of the Collaboration

  • Objective: The collaboration aims to explore the potential of tegoprubart as an alternative to tacrolimus, a standard immunosuppressive drug used in organ transplantation. Tegoprubart is an anti-CD40L antibody being evaluated for its ability to prevent transplant rejection in islet cell, kidney, and xeno transplantation.

  • Clinical Trial: Tegoprubart will be utilized in Cohort C of Sernova’s Phase 1/2 clinical trial. This trial involves patients with Type 1 Diabetes and focuses on the use of the Cell Pouch Bio-hybrid Organ, a novel approach in diabetes treatment.

  • Advantages of Tegoprubart: Unlike tacrolimus, which has potential toxicity towards insulin-producing beta cells and a challenging side effect profile, tegoprubart offers a promising alternative with potentially fewer adverse effects.

Company Overview

Sernova Biotherapeutics Inc., based in London, Canada, is a health care biotechnology company dedicated to developing treatments for insulin-dependent diabetes. The company, which went public on April 12, 1999, at the Toronto Stock Exchange, has a market capitalization of 49,270,000 CAD. Despite a negative price-to-earnings ratio of -2.23, Sernova continues to focus on innovative solutions in diabetes care.

Market Context

As of July 7, 2025, Sernova’s stock closed at 0.16 CAD, with a 52-week high of 0.34 CAD on September 5, 2024, and a low of 0.14 CAD on July 6, 2025. The company operates within the biotechnology sector of the health care industry, primarily listed on the Toronto Stock Exchange.

This collaboration marks a significant step in Sernova’s ongoing efforts to provide a functional cure for Type 1 Diabetes, potentially transforming the treatment landscape for millions of patients worldwide. For more information, visit Sernova’s website .